Also known as Farxiga and Forxiga.
Oral orforglipron showed 5–11% weight loss at 72 weeks and 1.2–1.9 percentage‑point HbA1c reductions; CHMP opinion now goes to the European Commission for an EU licence.
Phase 3 retatrutide and Foundayo results show large weight and A1C reductions and signals of cardiovascular benefit; Phase 2 eloraTZP and additional Mounjaro/Zepbound analyses also presented.
Oral GLP‑1 orforglipron reduced A1C and body weight more than oral semaglutide, dapagliflozin or placebo across three Phase‑3 trials; FDA filing planned by end of Q2 2026.
